Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation

OBJECTIVE: Leuprolide is an established luteinizing hormone–releasing hormone (LHRH) agonist used as first-line treatment in advanced prostate cancer. As different formulations and dosing schedules are likely to have economic implications, we aimed to evaluate their efficacy, safety, and costs in ni...

Descripción completa

Detalles Bibliográficos
Autores principales: Wex, Jaro, Sidhu, Manpreet, Odeyemi, Isaac, Abou-Setta, Ahmed M, Retsa, Peny, Tombal, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699057/
https://www.ncbi.nlm.nih.gov/pubmed/23836996
http://dx.doi.org/10.2147/CEOR.S44855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699057/
https://www.ncbi.nlm.nih.gov/pubmed/23836996
http://dx.doi.org/10.2147/CEOR.S44855

Ejemplares similares